NT-proBNP and Major Adverse Cardiovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Who Received Primary Percutaneous Coronary Intervention: A Prospective Cohort Study
Table 1
Baseline characteristics of the participants.
NT-proBNP (pg/mL, min to max)
Low (T1) (70–891.3)
Middle (T2) (896–2,538)
High (T3) (2,540–35,000)
Number
135
135
135
Age (years, mean ± sd)
57.27 ± 11.73
59.16 ± 11.33
64.88 ± 12.39
Sex (n (%))
Female
15 (11.11%)
22 (16.3%)
33 (24.44%)
Male
120 (88.89%)
113 (83.70%)
102 (75.56%)
Hypertension (n (%))
No
62 (45.93%)
68 (50.37%)
47 (34.81%)
Yes
73 (54.07%)
67 (49.63%)
88 (65.19%)
Hyperlipidemia (n (%))
No
90 (66.67%)
88 (65.19%)
92 (68.15%)
Yes
45 (33.33%)
47 (34.81%)
43 (31.85%)
Diabetes (n (%))
No
113 (83.7%)
105 (77.78%)
107 (79.26%)
Yes
22 (16.3%)
30 (22.22%)
28 (20.74%)
Prior MI (n (%))
No
131 (97.04%)
130 (96.3%)
126 (93.33%)
Yes
4 (2.96%)
5 (3.7%)
9 (6.67%)
Smoking (n (%))
No
67 (49.63%)
85 (62.96%)
86 (63.7%)
Yes
68 (50.37%)
50 (37.04%)
49 (36.3%)
Killip class (n (%))
I
125 (92.59%)
115 (85.19%)
89 (65.93%)
II
8 (5.93%)
11 (8.15%)
23 (17.04%)
III
1 (0.74%)
6 (4.44%)
15 (11.11%)
IV
1 (0.74%)
3 (2.22%)
8 (5.93%)
Time from symptom onset to balloon dilatation (h; median, Q1–Q3)
6 (4–8)
6 (4.5–10)
7 (5–11)
Time from admission to balloon dilatation (min; median, Q1–Q3)
73 (52.5–96)
72 (51–89)
73 (54–98)
Number of implanted stents (n (%))
PTCA
7 (5.19%)
3 (2.22%)
6 (4.44%)
1-stent
102 (75.56%)
101 (74.81%)
88 (65.19%)
2-stent
24 (17.78%)
28 (20.74%)
35 (25.93%)
3-stent
2 (1.48%)
3 (2.22%)
6 (4.44%)
Number of used balloons (n (%))
1-balloon
111 (82.22%)
114 (84.44%)
104 (77.04%)
2-balloon
23 (17.04%)
18 (13.33%)
31 (22.96%)
3-balloon
1 (0.74%)
3 (2.22%)
0 (0%)
Pre-PCI TIMI grade (n (%))
TIMI0
95 (70.37%)
95 (70.37%)
112 (82.96%)
TIMI1
20 (14.81%)
23 (17.04%)
14 (10.37%)
TIMI2
20 (14.81%)
17 (12.59%)
9 (6.67%)
Post-PCI TIMI grade (n (%))
TIMI0
2 (1.49%)
1 (0.74%)
0 (0%)
TIMI1
0 (0%)
0 (0%)
1 (0.74%)
TIMI2
4 (2.99%)
8 (5.93%)
9 (6.67%)
TIMI3
128 (95.52%)
126 (93.33%)
125 (92.59%)
Infarction-related artery (n (%))
LM
2 (1.48%)
3 (2.22%)
4 (2.96%)
LAD
55 (40.74%)
66 (48.89%)
74 (54.81%)
LCX
19 (14.07%)
14 (10.37%)
12 (8.89%)
RCA
59 (43.7%)
52 (38.52%)
45 (33.33%)
Use of thrombus aspiration catheter (n (%))
No
128 (94.81%)
122 (90.37%)
128 (94.81%)
Yes
7 (5.19%)
13 (9.63%)
7 (5.19%)
Applied IABP (n (%))
No
132 (97.78%)
128 (94.81%)
118 (87.41%)
Yes
3 (2.22%)
7 (5.19%)
17 (12.59%)
Temporary pacemaker (n (%))
No
119 (88.15%)
113 (83.70%)
115 (85.19%)
Yes
16 (11.85%)
22 (16.30%)
20 (14.81%)
ST-segment resolution (n (%))
No
22 (16.3%)
34 (25.19%)
52 (38.52%)
Yes
113 (83.7%)
101 (74.81%)
83 (61.48%)
CK peak value (U/L; median, Q1–Q3)
1,874 (943.5–3,314.65)
2,544 (1,491.5–4,349.95)
3,032 (1,719–5,258.00)
CK-MB peak value (U/L; median, Q1–Q3)
166.6 (78.1–291)
227.6 (117.35–356.9)
240.9 (155.7–439.4)
TnI peak value (U/L, median, Q1–Q3)
5 (1.3–14.4)
9.52 (2.4–22.67)
12.00 (4.2–25)
NT-proBNP (pg/mL; median, Q1–Q3)
485.5 (285–674.4)
1,560 (1,139–1,962.5)
4,896 (3,510–7,805)
Note. was calculated using the Kruskal–Wallis H test. We divided the NT-proBNP values of all patients into three groups using the tertiles method: low, medium, and high, namely, T1, T2, and T3. LM, left main; LAD, left anterior descending; LCX, left circumflex artery; RCA, right coronary artery; IABP, intra-aortic balloon pump; PTCA, percutaneous transluminal coronary angioplasty; CK, creatine kinase; CK-MB, creatine kinase isoenzyme-MB.
